Skip to main content
Log In
Sign Up
Home
Stocks
Stock Screener
Stock Exchanges
Comparison Tool
Earnings Calendar
By Industry
Stock Lists
Top Analysts
Top Stocks
Corporate Actions
IPOs
Recent IPOs
IPO Calendar
IPO Statistics
IPO News
IPO Screener
ETFs
ETF Screener
Comparison Tool
New Launches
ETF Providers
News
Trending
Articles
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After Hours
Market Newsletter
Stock Analysis Pro
Watchlist
Collapse
Home
»
Analysts
»
Paul Mattels
Paul Mattels
Stock Analyst at Stifel
(n/a)
# 4,350
Out of 4,711 analysts
4
Total ratings
n/a
Success rate
-20.75%
Average return
Main Sectors:
Healthcare
Top Industries:
Biotechnology
Stocks Rated by Paul Mattels
Stock
Action
Price Target
Current
Upside
Ratings
Updated
DNLI
Denali Therapeutics
Upgrades:
Buy
$37
$21.45
+72.49%
3
Dec 16, 2024
ALEC
Alector
Initiates:
Buy
$44
$1.86
+2,265.59%
1
Feb 19, 2020
DNLI
Denali Therapeutics
Dec 16, 2024
Upgrades:
Buy
Price Target:
$37
Current: $21.45
Upside:
+72.49%
3 Ratings
View All
ALEC
Alector
Feb 19, 2020
Initiates:
Buy
Price Target:
$44
Current: $1.86
Upside:
+2,265.59%
1 Ratings
View All